에 대한 최신 뉴스 Ascendis Pharma (NASDAQ:ASND) 주식

ASCENDIS PHARMA A/S - ADR

Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Bridgewater,,Nj,,Usa,-,August,23,,2022:,Bausch,Health,Us

Mid Cap

News

Movers

Trading Ideas

ASND

BLCO

EWTX

NUVL

POWL

지난주 연방준비제도(연준)가 금리를 50bp(베이시스 포인트) 인하하기로 결정하면서 기술, 건설, 산업, 기계 그리고 금융 부문 전반에 걸쳐 주가가 상승했다. 지난주 가장 좋은 실적을 보인 중형주 7종목은 다음과 같다. 여러분의 포트폴리오에 포함되어 있나요?

바우쉬 헬스와 엣지와이즈는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 15일-9월 21일)

FedEx planes.

Large Cap

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 2024년 ESMO 연례 회의에서 발표되었다고 발표했다.

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma AS

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 21.51% on an annualized basis producing an average annual return of 32.45%. Currently, Ascendis Pharma has a market capitalization of $10.26 billion. 
Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $68,514.06 today based on a price of $170.60 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746540918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years

Biotech

Events

General

AscendisTto Share Data From Hypoparathyroidism, Achondroplasia, And Growth Hormone Deficiency Programs During ESPE & ESE 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Vikram Purohit upgraded the rating for Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) from Equal-Weight to Overweight and raised the price target from $180 to $250. Ascendis Pharma shares closed at $172.06 on Friday. <a href="https://www.benzinga.com/quote/ASND/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Brian McNamara upgraded Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) from Hold to Buy and boosted the price target from $54 to $67. Worthington Enterprises shares closed at $51.99 on Friday. <a href="https://www.benzinga.com/quote/WOR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Stephen Bersey upgraded Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from Reduce to Hold and raised the price target from $77 to $99. Twilio shares closed at $100.11 on Friday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst John Ivankoe upgraded the rating for The Wendy&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) from Neutral to Overweight but lowered the price target from $17 to $15. Wendy&#8217;s shares closed at $12.55 on Friday. <a href="https://www.benzinga.com/quote/WEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Aaron Kessler upgraded Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) from Neutral to Buy and announced a $165 price target. Reddit shares closed at $113.83 on Friday. <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TWLO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="567" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-1024x567.png" alt="" class="wp-image-901223" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-1024x567.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

RDDT

TWLO

This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Morgan Stanley analyst Vikram Purohit upgrades Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) from Equal-Weight to Overweight and raises the price target from $180 to $250.

Morgan Stanley Upgrades Ascendis Pharma to Overweight, Raises Price Target to $250

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and raises the price target from $205 to $210.

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $210

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $200 to $245.

JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $245

Wedbush analyst Yun Zhong maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and raises the price target from $181 to $212.

Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $212

Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and raises the price target from $260 to $280.

Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $280

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) reported quarterly losses of $(1.66) per share which missed the analyst consensus estimate of $(1.46) by 13.7 percent. This is a 33.6 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $106.16 million which beat the analyst consensus estimate of $94.64 million by 12.17 percent. This is a 1.94 percent increase over sales of $104.15 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Ascendis Pharma Q1 EPS $(1.66) Misses $(1.46) Estimate, Sales $106.16M Beat $94.64M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-01. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ascendis Pharma to report an earnings per share (EPS) of $-1.51.
The announcement from Ascendis Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.52 in the last quarter, leading to a 12.96% increase in the share price on the following day.
Here's a look at Ascendis Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.20</td>
<td>-1.52</td>
<td>-1.56</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.68</td>
<td>-1.89</td>
<td>-2.06</td>
<td>-2.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>13.0%</td>
<td>2.0%</td>
<td>-11.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Ascendis Pharma were trading at $166.58 as of April 29. Over the last 52-week period, shares are up 18.7%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ASND/earnings">To track all earnings releases for Ascendis Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Ascendis Pharma's Earnings Potential

RBC Capital analyst Luca Issi initiates coverage on Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform rating and announces Price Target of $205.

Initiation

RBC Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $205

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 10 years by 45.5% on an annualized basis producing an average annual return of 55.38%. Currently, Ascendis Pharma has a market capitalization of $9.32 billion. 
Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 10 years ago, it would be worth $81,183.25 today based on a price of $155.06 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744747219_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.

Ascendis Submits New Drug Application To FDA For TransCon CNP For Treatment Of Children With Achondroplasia.

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has risen 9.48% since its last report. The company recently reported that it has 4.38 million shares sold short, which is 8.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743002120_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 5.60%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Ascendis Pharma's Recent Short Interest

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 20.52% on an annualized basis producing an average annual return of 31.71%. Currently, Ascendis Pharma has a market capitalization of $10.13 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $6,400.59 today based on a price of $168.50 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742921108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $168 to $200.

JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $200

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 19.62% on an annualized basis producing an average annual return of 31.01%. Currently, Ascendis Pharma has a market capitalization of $9.09 billion. 
Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $55,812.96 today based on a price of $151.93 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741122010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $170 to $200.

Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200

On Wednesday, BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">consensus of 53 cents</a>.
The company reported sales of $747.31 million, beating the consensus of $713.44 million. Total Revenues increased 16% year over year, driven by Voxzogo contributions from new <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43829778/biomarin-reports-fourth-quarter-and-full-year-2024-results-sets-full-year-2025-guidance" rel="noreferrer noopener">patient starts in all regions</a>.
In the quarter, revenues from BioMarin's Enzyme Therapies increased 9%, driven by increased patient demand in all regions and the timing of large government orders in certain regions outside the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43708807/why-is-rare-disease-focused-ascendis-pharma-stock-trading-higher-on-thursday" rel="noreferrer noopener">Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?</a>
Guidance: BioMarin Pharmaceutical expects fiscal year 2025 adjusted EPS of $4.20-$4.40 versus consensus of $3.04. The company expects 2025 sales of $3.1 billion-$3.2 billion versus a consensus of $3.11 billion.
"We expect 2025 to be another year of strong execution and growth in our Skeletal Conditions business unit, led by the continued global expansion of VOXZOGO for achondroplasia&#8230;In summary, we expect continued high performance as we benefit from BioMarin's revamped corporate strategy and operating model in 2025 and beyond," said Alexander Hardy, President and CEO of BioMarin.
In 2025, the company will continue to implement additional components of the $500 million cost transformation program announced in September of 2024, with full realization of benefits expected in 2026.
This ongoing integration of efficiencies in 2025 will enable BioMarin to realize a 40% adjusted operating margin in 2026.
William Blair notes that while BioMarin achieved its financial targets in 2024, its current valuation already accounts for expected revenue growth over the next 12–18 months.
Analyst Sami Corwin sees the limited expansion of Voxzogo's market until 2030–2031, when potential approvals for idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency could broaden its reach. A smaller boost may come in 2027 if its label expands to hypochondroplasia (HCH).
Corwin also flags Ascendis Pharma A/S' (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) navepegritide as a potential challenge for Voxzogo, with a near-term stock overhang as Ascendis moves toward a possible NDA submission in early 2025.
Beyond Voxzogo, BioMarin's enzyme therapy unit provides stable but modest revenue growth, though upcoming competition for Palynziq in 2025 could affect its compound annual growth rate.
Analyst Reaction:
<ul>
<li>BofA Securities maintains BioMarin with a Buy, raising the price target from $99 to $103.</li>
<li>Piper Sandler maintains BioMarin with an Overweight rating while raising the price target from $122 to $126.</li>
</ul>
Price Action: BMRN stock is up 3.19% at $67.70&nbsp;at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43846533/alibaba-q3-earnings-revenue-and-eps-beat-eyes-global-e-commerce-profitability-in-fy25-increase-investments-in-ai" target="_blank" rel="noreferrer noopener">Alibaba Q3 Earnings: Revenue And EPS Beat, Eyes Global E-Commerce Profitability In FY25, Increase Investments In AI</a></li>
</ul>

Analyst Color

Guidance

Health Care

Why Is BioMarin Stock Trading Higher On Thursday?

Press Releases

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Ascendis Pharma Reports First Quarter 2025 Financial Results

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Morgan Stanley

RBC Capital

JP Morgan

Wedbush

Evercore ISI Group

지난주 연방준비제도(연준)가 금리를 50bp(베이시스 포인트) 인하하기로 결정하면서 기술, 건설, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40937291/bank-stocks-hit-inflection-point-after-feds-50-basis-point-cut-analyst-reveal-top-p" target="_blank" rel="noreferrer noopener">산업, 기계 그리고 금융 부문</a> 전반에 걸쳐 주가가 상승했다.
지난주 가장 좋은 실적을 보인 중형주 7종목은 다음과 같다. 여러분의 포트폴리오에 포함되어 있나요?
1. 엣지와이즈 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>)의 주식은 회사가 건강한 피험자를 대상으로 한 1상 시험의 EDG-7500 톱라인 데이터와 <a href="https://www.benzinga.com//node/40940696" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">폐쇄성 HCM 환자를 대상</a>으로 한 2상 CIRRUS-HCM 시험의 단일 용량군에 대한 상위 데이터를 발표한 후 주가는 50.19% 급등했다.
2. 바우쉬 + 롬 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>)의 주식은 <a href="https://www.benzinga.com//node/40884021" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">매각을 검토 중이라는 보도</a>가 나온 후 28.36% 상승했다.
3. 바우쉬 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>)의 주식은 회사의 자회사인 바우쉬 + 롬 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>)가 매각을 검토 중이라는 보도가 나온 후 27.06% 상승했다.
4. 아센디스 파마 A/S(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>)의 주식은 회사가 희귀 왜소증 치료제의 주요 임상 시험 <a href="https://www.benzinga.com//node/40882593" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">데이터</a>를 발표한 후 26.87% 상승했다.
5. 뉴발런트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40865049" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">ROS1 및 ALK 양성 NSCLC 프로그램의 결과를 강조</a>하고 개발 일정을 가속화한 후  23.50% 상승했다. 이 회사는 또한 3억 5천만 달러의 공모를 발표했으며 여러 회사가 각각의 <a href="https://www.benzinga.com/quote/nuvl/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주식 가격 예측</a>을 높였다.
6. 파월 인더스트리즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>)의 주식은 연준의 금리 50bp 인하 발표 이후 산업 전반의 주식이 상승하면서 22.61% 상승했다. 이는 투자와 경제 성장을 지원할 수 있다.
7. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식은 21.28% 상승했다.
또한 읽어보세요:
&#8211; <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%98%EC%8A%A4%ED%85%94%EB%A0%88%EC%9D%B4%EC%85%98-%EB%B0%8F-%EC%B9%B4%EB%B0%94%EB%82%98%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">콘스텔레이션 및 카바나는 지난주 최고 성과를 보여준 11개 대형주 중 일부 (9월 16일-9월 20일)</a>
&#8211; <a href="https://kr.benzinga.com/news/usa/stocks/%EB%85%B8%EB%B3%B4-%EB%85%B8%EB%94%94%EC%8A%A4%ED%81%AC-%EC%B8%84%EC%9D%B4-%EB%B0%8F-%ED%8E%98%EB%8D%B1%EC%8A%A4%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)</a>
Photo by JHVEPhoto via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">2024년 ESMO 연례 회의</a>에서 발표되었다고 발표했다.
2. Joint Stock Company Kaspi.kz(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>)의 주식이 21.66% 급락했다. 이는 컬퍼 리서치(Culper Research)가 <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이 회사에 대한 공매도 보고서를 발표</a>한 후 주가는 21.66% 하락했다.
3. 바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>)의 주식이 16.74% 하락했다. 이는 경쟁사인 아센디스 파마(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>)의 <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">강력한 왜소증 치료제 데이터</a> 발표 이후 발생한 일이다.
4. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식이 <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">지난주</a> 13.26% 하락했다.
5. 페덱스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)의 주식은 회사가 예상보다 나쁜 1분기 재무 결과를 보고하고 <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스를 하향 조정</a>한 후 11.08% 하락했다.
6. 바이오엔텍 SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)의 주식이 9.01% 하락했다. 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)와 바이오엔텍은 유럽 연합에서 오미크론(omicron) KP.2 적응 <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">코로나19 백신</a>에 대해 긍정적인 CHMP 의견을 받았다.
7. 아서 J 갤러거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>)의 주식이 7.17% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>한 후 발생한 일이다.
8. 츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주식이 6.97% 하락했다. 이는 회사가 주식 공모와 <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">동시 주식 매입</a>을 발표한 후 발생한 일이다.
9. 노보 노디스크 A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 주식은 비만 환자를 대상으로 한 몬루나반트(monlunabant)의 <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">중간 단계 연구 결과가 헤드라인</a>을 장식한 후 6.93% 하락했다.
10. 머피 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>)의 주식이 6.90% 하락했다. 이는 JP 모건이 주식 등급을 중립에서 비중축소(Underweight)로 하향 조정했지만 <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 $415에서 $435로 상향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%98%EC%8A%A4%ED%85%94%EB%A0%88%EC%9D%B4%EC%85%98-%EB%B0%8F-%EC%B9%B4%EB%B0%94%EB%82%98%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">콘스텔레이션 및 카바나는 지난주 최고 성과를 보여준 11개 대형주 중 일부 (9월 16일-9월 20일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Ascendis Pharma

뉴스

에 대한 최신 뉴스 Ascendis Pharma (NASDAQ:ASND) 주식

월요일, 9월 23, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌